Beam Therapeutics Inc (BEAM)

Currency in USD
16.85
-0.01(-0.06%)
Closed·
17.47+0.62(+3.68%)
·
BEAM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BEAM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.8417.64
52 wk Range
13.5335.25
Key Statistics
Prev. Close
16.86
Open
17
Day's Range
16.84-17.64
52 wk Range
13.53-35.25
Volume
1.74M
Average Volume (3m)
2.29M
1-Year Change
-35.32%
Book Value / Share
10.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BEAM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
45.92
Upside
+172.54%
Members' Sentiments
Bearish
Bullish
ProTips
8 analysts have revised their earnings upwards for the upcoming period

Beam Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Beam Therapeutics Inc Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Compare BEAM to Peers and Sector

Metrics to compare
BEAM
Peers
Sector
Relationship
P/E Ratio
−4.2x−1.3x−0.6x
PEG Ratio
0.03−0.050.00
Price/Book
1.6x1.7x2.6x
Price / LTM Sales
27.5x8.3x3.3x
Upside (Analyst Target)
155.2%272.0%39.1%
Fair Value Upside
Unlock27.5%5.4%Unlock

Analyst Ratings

13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 45.92
(+172.54% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-1.00 / -1.11
Revenue / Forecast
8.47M / 12.77M
EPS Revisions
Last 90 days

BEAM Income Statement

People Also Watch

24.61
IRDM
-1.64%
53.05
CRSP
-0.90%
73.66
TEM
+0.59%
45.57
BMNR
-1.00%

FAQ

What Stock Exchange Does Beam Trade On?

Beam is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Beam?

The stock symbol for Beam is "BEAM."

What Is the Beam Market Cap?

As of today, Beam market cap is 1.66B.

What Is Beam's Earnings Per Share (TTM)?

The Beam EPS (TTM) is -4.49.

When Is the Next Beam Earnings Date?

Beam will release its next earnings report on 09 Nov 2025.

From a Technical Analysis Perspective, Is BEAM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Beam Stock Split?

Beam has split 0 times.

How Many Employees Does Beam Have?

Beam has 509 employees.

What is the current trading status of Beam (BEAM)?

As of 29 Aug 2025, Beam (BEAM) is trading at a price of 16.85, with a previous close of 16.86. The stock has fluctuated within a day range of 16.84 to 17.64, while its 52-week range spans from 13.53 to 35.25.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.